Phase 2 trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

被引：0
|
作者：
Obara, Grzegorz
Sun, Jichao
Loo, Deryk
Bohac, Gerry C.
机构：
[1] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[2] MacroGenics Inc, Rockville, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS6102
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN)
    Obara, G.
    Sun, J.
    Loo, D.
    Bohac, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S814 - S814
  • [2] Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial
    Colevas, D. A.
    Misiukiewicz, K.
    Pearson, A. T.
    Fayette, J.
    Bauman, J. R.
    Cupissol, D.
    Saada-Bouzid, E.
    Adkins, D. R.
    Marie, D. B.
    Cornen, S. L.
    Andre, P.
    Carrette, F.
    Rotolo, F.
    Boyer Chammard, A.
    Cohen, R. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S1432 - S1432
  • [3] Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008-03.
    Guigay, J.
    Fayette, J.
    Dillies, A.
    Sire, C.
    Kerger, J. N.
    Tennevet, I.
    Machiels, J. H.
    Zanetta, S.
    Pointreau, Y.
    Le Moal, L. Bozec
    Ribere, L. Brugel
    Henry, S.
    Temam, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] CETUXIMAB PLUS PLATINUM-BASED THERAPY FIRST-LINE IN PATIENTS WITH RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN): A QUALITY OF LIFE (QOL) ANALYSIS OF THE EXTREME TRIAL
    Herrero, F. Rivera
    Hitt, R.
    Kawecki, A.
    Rottey, S.
    Peyrade, F.
    Vynnychenko, I.
    Curran, D.
    Kisker, O.
    Gross, A.
    Vermorken, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 219 - 219
  • [5] A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).
    Rischin, Danny
    Boyer, Michael J.
    Brzezniak, Christina E.
    Colevas, A. Dimitrios
    Doebele, Robert Charles
    Gilbert, Jill
    Gitlitz, Barbara
    Khan, Saad A.
    Mehra, Ranee
    Seiwert, Tanguy Y.
    Kroll, Stew
    Pearce, Tillman E.
    Liu, Stephen V.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] PREDICTORS OF EFFICACY IN THE EXTREME STUDY: CETUXIMAB PLUS PLATINUM-BASED THERAPY FIRST-LINE IN PATIENTS WITH RECURRENT AND/OR METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
    Vermorken, J. B.
    Mesia, R.
    Remenar, E.
    Erfan, J.
    Zabolotnyy, D.
    Benasso, M.
    Koralewski, P.
    Gross, A.
    Stroh, C.
    Bokemeyer, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 217 - 217
  • [7] Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)
    Choong, N. W.
    Cohen, E. E.
    Kozloff, M. F.
    Taber, D.
    Wade, J. L., III
    Hu, S.
    Ivy, S. P.
    Nichols, K.
    Dekker, A.
    Vokes, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Cetuximab plus platinum-based therapy first-line in recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety results of a randomized phase III trial (EXTREME)
    Vermorken, J. B.
    Hitt, R.
    Geoffrois, L.
    Erfan, J.
    Kawecki, A.
    Zabolotnyy, D.
    Schueler, A.
    Knecht, R.
    Benasso, M.
    Kienzer, H.
    EJC SUPPLEMENTS, 2007, 5 (04): : 324 - 324
  • [9] REAL WORLD TREATMENT PATTERNS FOR FIRST LINE (1L) RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) PATIENTS
    Contente, M.
    Mtibaa, M.
    Hall, J.
    Bailey, H.
    Bailey, A.
    Di Rienzo, P.
    Polanco, C.
    Singh, P.
    VALUE IN HEALTH, 2019, 22 : S108 - S109
  • [10] Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results of phase II trial GORTEC 2008-03.
    Guigay, Joel
    Fayette, Jerome
    Dillies, Anne-Francoise
    Sire, Christian
    Kerger, Joseph N.
    Tennevet, Isabelle
    Machiels, Jean-Pascal H.
    Zanetta, Sylvie
    Pointreau, Yoann
    Le Moal, Laurence Bozec
    Ribere, Lydia Brugel
    Henry, Stefanie
    Temam, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345